HomeGeneticsConditionEthylmalonic encephalopathy
Back to Condition
Ethylmalonic encephalopathy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Ethylmalonic encephalopathy

Ethylmalonic encephalopathy is a rare, inherited metabolic disorder that primarily damages the nervous and vascular systems, often leading to severe developmental delays and life-threatening complications in early childhood.

Overview

Ethylmalonic encephalopathy is an inherited disorder that affects several body systems, particularly the nervous system. The signs and symptoms of this condition are typically apparent at birth or begin within the first few months of life. Problems affecting the nervous system generally worsen over time, and most affected individuals survive only into early childhood.

Symptoms and Clinical Features

The disorder is characterized by a range of neurological, vascular, and gastrointestinal symptoms, including:

  • Delayed development and the loss of previously acquired skills (developmental regression)
  • Weak muscle tone (hypotonia)
  • Seizures and abnormal movements
  • Rashes of tiny red spots (petechiae) caused by bleeding under the skin
  • Blue discoloration in the hands and feet due to reduced oxygen in the blood (acrocyanosis)
  • Chronic diarrhea

Frequency

About 70 individuals with ethylmalonic encephalopathy have been identified worldwide, primarily in Mediterranean and Arab populations. Although the condition appears to be very rare, researchers suggest that some cases may have been misdiagnosed as other neurological disorders.

Causes & Genetic Factors

This condition results from mutations in the ETHE1 gene. This gene provides instructions for producing an enzyme active in the mitochondria, which serve as the energy-producing centers of cells. The ETHE1 enzyme is part of a metabolic pathway that breaks down sulfide (H2S)—a molecule that is critical for normal cell function at very low levels but is highly toxic at elevated levels.

Mutations in the ETHE1 gene lead to a nonfunctional version of the enzyme or prevent the enzyme from being made at all. This shortage of functional enzyme prevents sulfide from being broken down, allowing it to accumulate in cells. The buildup of sulfide interferes with mitochondrial energy production and damages tissues and organs throughout the body. Researchers believe that the toxic effects of excess sulfide in the brain, muscles, blood vessels, and intestinal lining underlie the major features of the disorder.

Inheritance

This condition is inherited in an autosomal recessive pattern. This means both copies of the gene in each cell must have mutations for the individual to be affected. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Encephalopathy, petechiae, and ethylmalonic aciduria
  • EPEMA syndrome

Frequently Asked Questions

Management focuses on reducing toxic hydrogen sulfide levels: oral metronidazole (to suppress gut bacteria that produce H₂S) and N‑acetylcysteine (a sulfide‑detoxifying agent) are commonly used, along with supportive care for seizures, respiratory support, and aggressive treatment of infections that can precipitate decompensation.
definitive diagnosis is made by sequencing the ETHE1 gene to identify pathogenic mutations; many labs also measure elevated ethylmalonic acid in urine organic acid analysis as a supportive biochemical marker.
Sudden worsening of seizures, new onset of severe acrocyanosis, rapid increase in petechial rash, unexplained fever, or acute respiratory distress require emergent medical attention, as they may signal a metabolic decompensation or life‑threatening vascular event.
Long‑term strategies include chronic low‑dose metronidazole, antioxidant supplementation (e.g., riboflavin, coenzyme Q10), regular physiotherapy for hypotonia, and early intervention services for developmental delays; liver transplantation has been reported in select cases and may halt disease progression, but eligibility is limited.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA